Publications<\/h2>\n\t\t\t\t![\"112-sarcoma-omteztirado-def\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/04\/112-sarcoma-omteztirado-def.jpg\" "\\"112-sarcoma-omteztirado-def\\"")
\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tIdentification of metastatic agents and the study of their biological role in developing sarcomas.
\nIdentification of new therapeutic targets and preclinical evaluation of new compounds to treat sarcomas (Xavier Garc\u00eda del Muro)
\nIdentification of new prognostic markers for sarcomas (Xavier Garc\u00eda del Muro)\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tCasali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Alava E, Dei Tos AP, del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez Pousa A, Martin Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande M, van der Graaf W, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S, ESMO Guidelines C, E, G. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<\/strong>. Ann. Oncol. 2022;33(1):20-33. doi:10.1016\/j.annonc.2021.09.005.<\/p>\nGounder MM, Razak AA, Somaiah N, Chawla S, Martin Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr\u00f6schel S, Hatcher H, Duffaud F, Herr\u00e1ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G\u00f6tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial<\/strong>. J. Clin. Oncol. 2022;40(22):2479-2490. doi:10.1200\/JCO.21.01829.<\/p>\nArchilla Ortega A, Domuro C, Martin Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity<\/strong>. J. Exp. Clin. Cancer Res. 2022;41(1):62-62. doi:10.1186\/s13046-022-02264-x.<\/p>\nPascual Pasto G, Castillo Ecija H, Unceta N, Aschero R, Resa Pares C, G\u00f3mez Caballero A, Vila Ubach M, Mu\u00f1oz Aznar O, Su\u00f1ol M, Burgue\u00f1o V, Gomez Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de \u00c1lava E, Tirado OM, Mora J, Carcaboso AM. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas<\/strong>. J Control Release. 2022;34281-92. doi:10.1016\/j.jconrel.2021.12.035.<\/p>\nGarc\u00eda Dom\u00ednguez DJ, Hajji N, L\u00f3pez Alemany R, S\u00e1nchez Molina S, Figuerola Bou E, Mor\u00f3n Civanto FJ, Rello Varona S, Andr\u00e9s Le\u00f3n E, Benito A, Keun HC, Mora J, Tirado \u00d3M, de \u00c1lava E, Hontecillas Prieto L. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1<\/strong>. Oncogene. 2022;41(18):2638-2650. doi:10.1038\/s41388-022-02279-w.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tFIS21126. TILS TREATMENT IN ADVANCED TUMORS WITH ALTERATIONS IN THE SWI\/SNF COMPLEX: THE TILTS STUDY<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 1081914,72. 2022-2025. PI: Mart\u00edn Liberal, Juan.<\/p>\n20MAR001. Molecular analysis of the metastatic process in developmental tumors. Fundaci\u00f3 TV3<\/strong>. Budget: 300000. 2020-2023. PI: MARTINEZ TIRADO, OSCAR.<\/p>\n19ACL231. ESTUDIO DE FASE 1B\/2 DE LY3200882 Y PEMBROLIZUMAB EN PACIENTES CON C\u00c1NCER AVANZADO<\/strong>. Budget: 267326,4. 2019- . PI: Mart\u00edn Liberal, Juan.<\/p>\n2021-070-1. PROSPECTIVE COLLECTION OF DONOR TISSUE AND WHOLE BLOOD OR LEUKAPHERESIS PRODUCT FROM PATIENTS WITH SOLID TUMOURS TO ENABLE DEVELOPMENT OF METHODS FOR THE MANUFACTURING OF CLONAL NEOANTIGEN T CELL PRODUCTS (cNeT). ACHILLES THERAPEUTICS UK LIMITED<\/strong>. Budget: 220881,12. 2021- . PI: Mart\u00edn Liberal, Juan.<\/p>\n20ACL101. A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. REGENERON PHARMACEUTICAL, INC<\/strong>. Budget: 203366,88. 2020- . PI: Mart\u00edn Liberal, Juan.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT064-EPH2A APTAMER AND USES THEREOF
\nIP: Oscar Mart\u00ednez tirado
\nEP19382451\nLicense: EPH2A APTAMER AND USES THEREOF
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\nSpin-off: Aptadel Therapeutics
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tDevelopment of a new orthotopic model for studying sarcoma metastasis
\nDescription of Ewing’s sarcoma methylome\n\t\t\t\t![\"Oscar-Martinez-Tirado\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/11\/Oscar-Martinez-Tirado-150x150.jpg\" "\\"Oscar-Martinez-Tirado\\"")
\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t![\"Xavier-Garcia-del-Muro\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/11\/Xavier-Garcia-del-Muro-150x150.jpg\" "\\"Xavier-Garcia-del-Muro\\"")
\n\n\t\tGarc\u00eda del Muro, Solans Xavier\n\t<\/h4>\n\n\t\t\n\t\tgarciadelmuro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tRELATED LINKS\n\t<\/h4>\n\n\t\t\n\t\tFacebook\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\t@SRGIDIBELL\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\t@omt2007\n\t\t<\/a>\n\t<\/h4>\n\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t\n- Martinez Tirado, Oscar<\/li>\n<\/ul>\n\t\t\t\t\t\tPrincipal investigators\n\t\t\t\t\t\t\t\t\t\t\t
\n- Garc\u00eda del Muro, Solans Xavier<\/li>\n<\/ul>\n\t\t\t\t\t\tClinical researchers\n\t\t\t\t\t\t\t\t\t\t\t
\n- Sanjuan Garriga, Francesc Xavier<\/li>\n<\/ul>\n\t\t\t\t\t\tPostdoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t
\n- Chic\u00f3n Bosch, Mariona<\/li>\n<\/ul>\n\t\t\t\t\t\tPredoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t
\n- Sanchez Serra, Sara<\/li>\n<\/ul>\n\t\t\t\t\t\tScientific support\n\t\t\t\t\t\t\t\t\t\t\t
\n- L\u00f3pez Alemany, Roser<\/li>\n
- Gris Lorente, Manuel<\/li>\n
- Rosas Lape\u00f1a, Marta<\/li>\n<\/ul>\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and the University of Iowa developed a new molecule for targeted treatment against cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL receives 1.2 million euros in grants to promote scientific research and its transfer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPharmacological inhibition of a protein reduces metastases in Ewing’s Sarcoma in vivo and in vitro models<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe spin-off Aptadel selected to be part of BCN Health Booster<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA new algorithm classifies different types of sarcoma<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/02\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAptadel, the new IDIBELL’s spinoff<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL’s sarcoma research group will receive one of the new grants of AECC Innova<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/09\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentified a determinant protein for tumor progression and metastasis in childhood cancer Rhabdomyosarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/01\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and Alba P\u00e9rez Foundation take a new step forward to develop a treatment for Ewing’s sarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/12\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL’s health innovation model visits Barcelona and Japan<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/10\/2018\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"Sarcoma Summary The Sarcoma research group, led by \u00d2scar Martinez-Tirado, is a multidisciplinary group which primarily aims to identify new metastatic markers and broaden the knowledge regarding their biological role in developing sarcomas, as well as identifying new therapeutic targets and validating new prognostic and predictive markers in sarcomas, through preclinical evaluation of new components […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 04:27:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807\/revisions"}],"predecessor-version":[{"id":23468,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807\/revisions\/23468"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr\u00f6schel S, Hatcher H, Duffaud F, Herr\u00e1ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G\u00f6tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial<\/strong>. J. Clin. Oncol. 2022;40(22):2479-2490. doi:10.1200\/JCO.21.01829.<\/p>\n Archilla Ortega A, Domuro C, Martin Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity<\/strong>. J. Exp. Clin. Cancer Res. 2022;41(1):62-62. doi:10.1186\/s13046-022-02264-x.<\/p>\n Pascual Pasto G, Castillo Ecija H, Unceta N, Aschero R, Resa Pares C, G\u00f3mez Caballero A, Vila Ubach M, Mu\u00f1oz Aznar O, Su\u00f1ol M, Burgue\u00f1o V, Gomez Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de \u00c1lava E, Tirado OM, Mora J, Carcaboso AM. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas<\/strong>. J Control Release. 2022;34281-92. doi:10.1016\/j.jconrel.2021.12.035.<\/p>\n Garc\u00eda Dom\u00ednguez DJ, Hajji N, L\u00f3pez Alemany R, S\u00e1nchez Molina S, Figuerola Bou E, Mor\u00f3n Civanto FJ, Rello Varona S, Andr\u00e9s Le\u00f3n E, Benito A, Keun HC, Mora J, Tirado \u00d3M, de \u00c1lava E, Hontecillas Prieto L. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1<\/strong>. Oncogene. 2022;41(18):2638-2650. doi:10.1038\/s41388-022-02279-w.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t FIS21126. TILS TREATMENT IN ADVANCED TUMORS WITH ALTERATIONS IN THE SWI\/SNF COMPLEX: THE TILTS STUDY<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 1081914,72. 2022-2025. PI: Mart\u00edn Liberal, Juan.<\/p>\n 20MAR001. Molecular analysis of the metastatic process in developmental tumors. Fundaci\u00f3 TV3<\/strong>. Budget: 300000. 2020-2023. PI: MARTINEZ TIRADO, OSCAR.<\/p>\n 19ACL231. ESTUDIO DE FASE 1B\/2 DE LY3200882 Y PEMBROLIZUMAB EN PACIENTES CON C\u00c1NCER AVANZADO<\/strong>. Budget: 267326,4. 2019- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 2021-070-1. PROSPECTIVE COLLECTION OF DONOR TISSUE AND WHOLE BLOOD OR LEUKAPHERESIS PRODUCT FROM PATIENTS WITH SOLID TUMOURS TO ENABLE DEVELOPMENT OF METHODS FOR THE MANUFACTURING OF CLONAL NEOANTIGEN T CELL PRODUCTS (cNeT). ACHILLES THERAPEUTICS UK LIMITED<\/strong>. Budget: 220881,12. 2021- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 20ACL101. A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. REGENERON PHARMACEUTICAL, INC<\/strong>. Budget: 203366,88. 2020- . PI: Mart\u00edn Liberal, Juan.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT064-EPH2A APTAMER AND USES THEREOF Sarcoma Summary The Sarcoma research group, led by \u00d2scar Martinez-Tirado, is a multidisciplinary group which primarily aims to identify new metastatic markers and broaden the knowledge regarding their biological role in developing sarcomas, as well as identifying new therapeutic targets and validating new prognostic and predictive markers in sarcomas, through preclinical evaluation of new components […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 04:27:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807\/revisions"}],"predecessor-version":[{"id":23468,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/1807\/revisions\/23468"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Oscar Mart\u00ednez tirado
\nEP19382451\nLicense: EPH2A APTAMER AND USES THEREOF
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\nSpin-off: Aptadel Therapeutics
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tDevelopment of a new orthotopic model for studying sarcoma metastasis
\nDescription of Ewing’s sarcoma methylome\n\t\t\t\t\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t
\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n\n\t\tGarc\u00eda del Muro, Solans Xavier\n\t<\/h4>\n
\n\t\t\n\t\tgarciadelmuro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tRELATED LINKS\n\t<\/h4>\n
\n\t\t\n\t\tFacebook\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@SRGIDIBELL\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@omt2007\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and the University of Iowa developed a new molecule for targeted treatment against cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL receives 1.2 million euros in grants to promote scientific research and its transfer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPharmacological inhibition of a protein reduces metastases in Ewing’s Sarcoma in vivo and in vitro models<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe spin-off Aptadel selected to be part of BCN Health Booster<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA new algorithm classifies different types of sarcoma<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/02\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAptadel, the new IDIBELL’s spinoff<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL’s sarcoma research group will receive one of the new grants of AECC Innova<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/09\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentified a determinant protein for tumor progression and metastasis in childhood cancer Rhabdomyosarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/01\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL and Alba P\u00e9rez Foundation take a new step forward to develop a treatment for Ewing’s sarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/12\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL’s health innovation model visits Barcelona and Japan<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/10\/2018\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"